Related Experiment Video
Updated: Sep 21, 2025
28:13
Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation
Published on: February 26, 2013
33.5K
Single Versus Dual Antiplatelet Therapy following Left Atrial Appendage Occlusion in Patients With High Bleeding Risk
Mohammed Mhanna1, Azizullah Beran1, Ahmad Al-Abdouh2
1Department of Internal Medicine, University of Toledo, Toledo, OH.
Current Problems in Cardiology
|June 1, 2022
Summary
Single antiplatelet therapy (SAPT) and dual antiplatelet therapy (DAPT) showed similar effectiveness in preventing device-related thrombosis after left atrial appendage occlusion. Further research is needed to confirm these findings for clinical practice.
Area of Science:
- Cardiology
- Interventional Cardiology
- Thrombosis Research
Background:
- Left atrial appendage occlusion (LAAO) is an alternative to oral anticoagulation for stroke prevention in atrial fibrillation.
- Patients at high risk for bleeding or with contraindications to oral anticoagulation require alternative antithrombotic strategies post-LAAO.
- The optimal antithrombotic regimen following LAAO in this specific patient population remains unclear.
Purpose of the Study:
- To compare the efficacy and safety of single antiplatelet therapy (SAPT) versus dual antiplatelet therapy (DAPT) after LAAO.
- To evaluate the rates of device-related thrombosis (DRT), stroke, and major bleeding between SAPT and DAPT groups.
- To assess the clinical utility of SAPT and DAPT in patients with high-risk or contraindications for oral anticoagulation post-LAAO.
Main Methods:
- Systematic review and meta-analysis of 14 observational studies.
- Inclusion of 3,151 patients who underwent LAAO and received either SAPT or DAPT.
- Comparative analysis of clinical outcomes including DRT, stroke, and major bleeding events.
Main Results:
- SAPT and DAPT demonstrated comparable effectiveness in preventing device-related thrombosis.
- A trend towards higher stroke risk with SAPT and higher major bleeding risk with DAPT was observed, but these did not reach statistical significance.
- No statistically significant differences were found in the primary efficacy and safety endpoints between the two antiplatelet strategies.
Conclusions:
- Current evidence suggests similar rates of device-related thrombosis between SAPT and DAPT following LAAO in high-risk patients.
- While trends suggest potential differences in stroke and bleeding risks, further investigation is required.
- Large-scale randomized controlled trials are necessary to definitively establish the optimal antiplatelet strategy post-LAAO for this patient cohort.
Related Concept Videos
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
658
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
658
01:27Coronary Artery Disease V: Interprofessional Care
41
Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
41
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
938
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
938
01:29Venous Thrombosis III: Interprofessional Care
32
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
32
01:18Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
1.3K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.3K